Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 16

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
1,2,3,4-Tetrahydroisoquinolines, among them the most interesting neuroprotective substance, an inhibitor of MAO, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), are endogenous compounds present in the central nervous system of mammals and humans. In this study, we investigated the effect of 1MeTIQ on morphine-induced analgesia, tolerance and abstinence syndrome as well as its effect on morphine-induced changes in dopamine metabolism in rat brain structures (nucleus accumbens, striatum, substantia nigra) using HPLC methodology. The experiments were carried out on male Wistar rats. Morphine analgesia was measured in the “hot-plate” test. To induce tolerance, morphine was given chronically (20 mg/kg i.p.) alone or following 1MeTIQ (50 mg/kg i.p.) injection. The development of dependence was assessed in the naloxone (2 mg/kg i.p.) precipitation test, after 10 days of morphine administration. The behavioral studies have shown that an endogenous compound, 1MeTIQ produced strong potentiation of morphine analgesia, prevented the development of morphine tolerance and inhibited expression of morphine abstinence syndrome in morphine-dependent rats. In neurochemical studies, we have demonstrated that 1MeTIQ antagonized morphine-induced changes in dopamine metabolism observed in rat brain structures. The main finding of this study was demonstration for the first time of an anti-abuse effect of an endogenous compound, 1MeTIQ, and its efficiency in counteracting morphine-induced addiction in the way useful from clinical point of view. The obtained results suggested a possibility of clinical application of 1MeTIQ in morphine addiction.
1,2,3,4,-Tetrahydroisochinolines (TIQ) are endogenous substances present in brain in low concentrations. Several TIQ derivatives are neurotoxic producing a Parkinson’s syndrome. In turn 1-methyl-1- ,2,3,4,-tetrahydroisochinoline (1MeTIQ) was found to reduce neuronal death in various models of neurotoxicity. Our previous results revealed that 1MeTIQ reduces excitotoxicity in the primary culture of rat cerebellar granule cells, inhibits glutamate evoked 45Ca accumulation in neurons and suppresses [3H]MK-801 binding to rat cortical membranes. Thus we hypothesized that this compound may be attributed to NMDA receptor antagonists. To verify this supposition, in the present study we compared the neuroprotective potential of 1MeTIQ with the established uncompetitive NMDA receptor antagonists MK-801 and memantine. The primary cultures of rat cerebellar granule neurons were briefly exposed to glutamate, and the substances tested were either co-applied with the excitotoxin or we tested their ability to induce tolerance to glutamate by pre- or post-conditioning. Consequently, 100, 250 or 500 µM 1MeTIQ, 0.5 µM MK-801 or 5 µM memantine were applied for 30 min either together with glutamate, 24 or 48 h before (pre-conditioning), or 0.5 h, 1 h and 3 h after (post-conditioning) exposure to 100 µM or 250 µM glutamate. Our results demonstrated that MK-801, memantine and 1MeTIQ induce an almost complete neuroprotection when co-applied with glutamate. Similar effects of 1MeTIQ and of the established NMDA receptor antagonists were observed in the pre-treatment experiments, even with 48 h lag between application of tested substances and the excitotoxic challenge. In the post-treatment experiments, MK-801 and memantine as well as 500 µM 1MeTIQ applied up to 3 h after brief exposition to glutamate significantly decreased the excitotoxic lesion, while 1MeTIQ in lower concentrations was ineffective. Thus, we demonstrated that 1MeTIQ acts as a weak NMDA receptor antagonist. The new finding of this study is that 1MeTIQ like MK-801 or memantine is neuroprotective when administered before and after exposure to glutamate. We suggest that 1MeTIQ induces long-lasting tolerance of cultured neurons to the excitotoxic insults, and consequently that the mechanism of neuroprotective effects of 1MeTIQ observed under various experimental conditions may be partially attributed to tolerance developing after pre- or post-treatment of neurons with this substance. The studies were supported by Polish MNiSW grant no. N N401 066438
Various endogenous teterahydroisochinoline derivatives present in the mammalian brain have been considered as neurotoxic substances. However 1-methyl-1,2,3,4-tetrahydroisochinoline (1MeTIQ) is known for its mild neuroprotective potential of the unclear mechanism. On the one hand 1MeTIQ exhibits anti-dopaminergic activity and reduces the neurotoxic effects of MPTP and rotenone, decreasing also the behavioral effects of MK-801 in rats in vivo. On the other hand the results of our previous study demonstrated that 1MeTIQ in vitro prevents glutamate-induced excitotoxicity in cultured neurons suggesting that this effect may be ascribed to its inhibitory effect on NMDA receptors. It is well known that the antagonists of NMDA receptors provide neuroprotection in brain ischemia, however the anti ischemic properties of 1MeTIQ were not tested previously. The aim of our present study was to verify in vitro putative antagonistic effects of 1MeTIQ on the NMDA receptors and to evaluate its neuroprotective potential in the animal models of brain ischemia. The receptor binding experiments using membranous fractions isolated from the rat brain cortex confirmed that 1MeTIQ in high micro molar concentrations inhibits in a concentration-dependent manner the specific binding of [3H] MK-801, while the binding of [3H]glutamate remains unaffected. The hypothesis that 1MeTIQ may be attributed to NMDA receptor antagonists acting as channel blockers was also supported by the results of experiments utilizing primary cultures of rat cerebellar granule cells submitted to acute NMDA and glutamate excitotoxicity. Under these conditions 1MeTIQ applied at high micro molar concentrations provided a pronounced neuroprotection and significantly inhibited generation of the calcium signal. The in vivo ischemic experiments demonstrated that application of 1MeTIQ in the dose of 50 mg/kg 30 min before the insult in the model of global forebrain ischemia in Mongolian gerbils or its repeated application in the same dose after hypoxia-ischemia in the rat model of perinatal asphyxia provided significant neuroprotection. In the gerbils treated with 1MeTIQ we observed the morphological and behavioral symptoms of neuroprotection and the postischemic hypothermia characteristic for medication of brain ischemia with the NMDA receptor antagonists. Collectively these data offer new arguments confirming the hypothesis that 1MeTIQ acts as a weak uncompetitive antagonist of NMDA receptors, providing the neuroprotection under various excitotoxic and ischemic conditions both in vitro and in vivo.
The efficacy of 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), a member of endogenous tetrahydroisoquinolines, in cocaine- and food-maintained responding in self-administration procedures under a fixed ratio 5 schedule of reinforcement as well as in cocaine and food seeking behaviors in male Wistar rats was examined. The effects of 1MeTIQ on cocaine discrimination and on basal locomotor activity were also assessed. In rats trained to self-administered either cocaine (0.5 mg/kg/injection) paired with the cue (light+tone) or food under a fixed ratio 5 schedule of reinforcement, 1MeTIQ (25 - 50 mg/kg) dose-dependently decreased the cocaine-maintained responding, but did not alter the food-maintained responding. 1MeTIQ (25 - 50 mg/kg) decreased the cocaine seeking behavior reinstated by a noncontingent presentation of cocaine (10 mg/kg, i.p.), but altered neither behavior reinstated by a discrete cue (tone+light) nor food-induced reinstatement. In rats trained to discriminate cocaine (10 mg/kg) from saline in water-reinforced fixed ratio 20 task, pretreatment with 1MeTIQ resulted in neither substitution nor significant alterations in the cocaine (1.25 - 10 mg/kg)-induced discriminative stimulus effects. 1MeTIQ (25 - 50 mg/kg) did not produce also a significant changes in basal horizontal activity. In conclusion, our present results outline a significance of exogenously applied 1MeTIQ in attenuating drug-evoked relapses to cocaine as well as the direct rewarding properties of cocaine (that model the cocaine-induced "high"), but not cocaine subjective effects. Moreover, a dissociation between effects of 1MeTIQ on cocaine vs. food-maintained responding was demonstrated.
BACKGROUND AND AIMS: In morphine addicted patients, chronic treatment with various abusers is interspersed with drugfree periods (periods of sleep or unsuccessful attempts to treat). These repeated withdrawal periods may intensify the withdrawal episode. These data inspired us to examine if repeated withdrawal periods has the effect on the severity of naloxone-induced withdrawal signs in rats. We also investigated the effect of A1 and A2A receptors in observed withdrawal signs. Additionally, to elucidate the mechanisms underlying the effects of repeated morphine withdrawal signs, neurochemical experiments were performed. METHODS: To obtain the state of dependence, the animals were treated with increasing doses of morphine, twice a day, for 8 days. To demonstrate the effect of sporadic treatment with morphine, we divided rats into two groups: continuously and sporadically treated with morphine. In sporadic group, morphine administration was modified by adding 3 morphine-free periods. On the 9th day of the study, the subsequent dose of morphine was injected. 1 hour later, the naloxone, was administrated for induction of morphine withdrawal signs in rats. Then, animals were placed into cylinders and jumpings were recorded for period 30 min. After decapitation, a neurochemical study, using HPLC-ED method was made. The concentration of dopamine and its metabolites was assessed in three brain structures (striatum, hippocampus, prefrontal cortex). RESULTS: We confirmed that sporadic treatment with morphine induced the intensification of morphine withdrawal signs, and administration of both adenosine agonists reduced the severity of them. In neurochemical experiments we demonstrated significant differences in the release in dopamine and its metabolites in studied brain areas. CONCLUSION: The recognition of neurochemical mechanisms, underlying the behavioral changes, may have an important role for further exploration of the various effects of repeated morphine withdrawal signs.
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.